🩺🌳When good clinical practice meets reducing environmental burden of healthcare: Rheumatologists can do a lot! Less is more ⬇️ Thank you @eular_org for planning environmental awareness sessions Looking forward to #greener congresses #EULAR2026 @RheumNow https://t.co/5FwARRi92m

• https://x.com/Nellziade/status/2062843363074703703/photo/1

#RheumMadness comes to #EULAR2026! Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly. @RheumNow https://t.co/lmgkJbTgBm

• https://x.com/DrMiniDey/status/2062842842406375826/photo/1

Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated: High carbon footprint! #EULAR2026 @rheumnow https://t.co/BAuzQuZ0Iv

• https://x.com/Nellziade/status/2062841554012610987/photo/1

#EULAR2026 OP0340 WK84 data of single arm Phase 2 Daratumumab (CD38 plasma depleter) weekly for 8 doses with background IS in N=10 #SLE: rapid reduction of antidsDNA & efficacy. 6/10 relapsed from WK20; 5/10 had low IgG and needed IVIG. Promising but Not so durable @RheumNow https://t.co/UrTywqkQ4F

• https://x.com/Yuz6Yusof/status/2062840252742471836/photo/1

What does remission look like for people living with PsA? Much more than the absence of swollen joints Absence of pain Skin management Ability to resume daily activities Sustained over time A definition not always reflected in our disease activity scores #POS0294 #EULAR2026 https://t.co/VCnMGAOVYm

• https://x.com/AurelieRheumo/status/2062840184509468983/photo/1
• https://x.com/AurelieRheumo/status/2062840184509468983/photo/1

Interesting poster #POS0939 from @SteZhao #EULAR2026 Long-term or recurrent antibiotic use in childhood associated w doubled risk of axSpA in HLA-B27+ individuals 11,611 HLA-B27+ UK biobank Recall bias? Yes but self-reported exposure validated with primary care data @RheumNow https://t.co/VmxI3BW6FE

• https://x.com/Nellziade/status/2062839948101722503/photo/1

Can AI read 20yrs of #RA X-rays as well as experts? RADAR algorithm scored 7,560 joints from the ESPOIR cohort: accuracy 0.94, sensitivity 0.92, specificity 0.95. AI-assisted radiographic scoring at scale and at the point of care may be here. @RheumNow #EULAR2026 OP0344

Have you ever thought of diclofenac as an environmental pollutant? Interesting insights from the carbon footprint of #rheumatology session at #EULAR2026 @rheumnow https://t.co/RJWB6DmiZh

• https://x.com/Nellziade/status/2062833468040482919/photo/1

#EULAR2026 OP0338 More evidence for treatment-to-target in #SLE. Longitudinal renal function analysis of Asia Pacific cohort: achieving LLDAS at least 50% of the time (LLDAS50) is assoc. with reduced eGFR decline independent of age, baseline eGFR, & renal involvement @RheumNow https://t.co/KduU1qtkhF

• https://x.com/Yuz6Yusof/status/2062831978899034502/photo/1

In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP. At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+ POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr

• https://x.com/RHEUMarampa/status/2062829262353125624/photo/1

Understanding how Bispecific T cell engagers work: remarkable mode of action! Let’s hope it works as well as in oncology! #teclistamab in #SSc #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/waSCXKA79Y

• https://x.com/Nellziade/status/2062824614451884035/photo/1
• https://x.com/Nellziade/status/2062824614451884035/photo/1

#EULAR2026 OP0336 Exploratory study of REGENCY RCT showed Obinutuzumab induced tissue depletion & histologic remission vs PBO. Interestingly, 53% OBI CRR non-responders had histologic remission. Better #lupus nephritis markers needed beyond proteinuria @RheumNow #EULARBest https://t.co/d8jPo9scvw

• https://x.com/Yuz6Yusof/status/2062823915534123181/photo/1

#CAR_T cell therapy in #SSc Promising results from the Breakfree-1 study (Zola-cel) on safety and preliminary efficacy on pFVC in 26 patients More data is needed #HOT session Pr Oliver Distler #EULAR2026 @RheumNow https://t.co/ZS1LnBLMu5

• https://x.com/Nellziade/status/2062823743164981421/photo/1
• https://x.com/Nellziade/status/2062823743164981421/photo/1
• https://x.com/Nellziade/status/2062823743164981421/photo/1
• https://x.com/Nellziade/status/2062823743164981421/photo/1

Looking forward to CAR T cell therapy trials in #SSc Phase 2 and 3 studies presented at #HOT session by Pr Oliver Distler #CAR_T #EULAR2026 @RheumNow https://t.co/bmXZpF2wKg

• https://x.com/Nellziade/status/2062821524097097918/photo/1
• https://x.com/Nellziade/status/2062821524097097918/photo/1

#EULAR2026 OP0335 Open label extension study of Phase II Ianalumab RCT in #SLE: some patients treated with IAN for up to 1 year, had persistent benefits (median 44 wks post-IAN) following Bcell recovery. Important info to judiciously treat while balancing infection risk @RheumNow https://t.co/DEkGMYwy3H

• https://x.com/Yuz6Yusof/status/2062820631477928349/photo/1